Examining the Cost, Benefits, and Safety of Using Dolutegravir as the First Treatment for HIV at a Major Hospital in South Gujarat
Not Applicable
- Conditions
- Health Condition 1: Z21- Asymptomatic human immunodeficiency virus [HIV] infection status
- Registration Number
- CTRI/2024/02/062200
- Lead Sponsor
- il
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Adult (=18 years of age) PLHIIV patient of any gender on first line ART for at least 6 months attending ART center
Exclusion Criteria
Patient not willing to participate
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method atural unit of effectiveness, monetary value, Quality adjusted life years and Disability adjusted life yearsTimepoint: After 16 months <br/ ><br>
- Secondary Outcome Measures
Name Time Method CD4 counts & viral load; <br/ ><br>Adverse drug reaction by analysis of causality, preventability & severity <br/ ><br>Associated comorbidities with HIVTimepoint: CD4 counts & viral load done at baseline & at six months; <br/ ><br>Adverse drug reaction by analysis of causality, preventability & severity at the time of reporting